Skip to content
Toggle navigation
Our Company
Our Science
ABCD Platform
Scientific Presentations
Focus Areas
Diabetic Eye Disease
Retinal Vein Occlusion
Wet Age Related Macular Degeneration
Our Pipeline
TARCOCIMAB TEDROMER
KSI-501
KSI-101
Our Culture
Join the Team
Investors & Media
Overview
Press Releases
ESG Report
Events and Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
Our Company
Our Science
ABCD Platform
Scientific Presentations
Focus Areas
Diabetic Eye Disease
Retinal Vein Occlusion
Wet Age Related Macular Degeneration
Our Pipeline
TARCOCIMAB TEDROMER
KSI-501
KSI-101
Our Culture
Join the Team
Investors & Media
Overview
Press Releases
ESG Report
Events and Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
Development of Anti-inflammatory Bispecific Trap-antibodies
July 1, 2024
By
1200 Page Mill Road
Palo Alto, CA 94304
United States of America